KODIAK SCIENCES INC. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
KODIAK SCIENCES INC. (KOD) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $106.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2026-08-13
- KODIAK SCIENCES INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-12-31 was $98.00K, a 104.17% increase year-over-year.
- KODIAK SCIENCES INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-09-30 was $0.00.
- KODIAK SCIENCES INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-12-31 was $48.00K, a 5.88% decline year-over-year.
- KODIAK SCIENCES INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-09-30 was $0.00.
- KODIAK SCIENCES INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2025 was $180.00K, a 68.22% increase from fiscal 2024.
- KODIAK SCIENCES INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2024 was $107.00K, a 41.21% decline from fiscal 2023.
- KODIAK SCIENCES INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2023 was $182.00K, a 4.60% increase from fiscal 2022.
- KODIAK SCIENCES INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2022 was $174.00K, a 64.05% decline from fiscal 2021.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $106.00K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $98.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $98.00K derived: sum of 2 quarters · filed 2026-03-31 | $180.00K 10-K · filed 2026-03-31 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $82.00K 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $82.00K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $48.00K derived: sum of 2 quarters · filed 2026-03-31 | $107.00K 10-K · filed 2026-03-31 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $59.00K 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $59.00K 10-Q · filed 2025-08-13 | |||
| 2023-12-31 | $51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $51.00K derived: sum of 2 quarters · filed 2026-03-31 | $182.00K 10-K · filed 2026-03-31 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $131.00K 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $131.00K 10-Q · filed 2024-08-14 | |||
| 2022-12-31 | $110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $110.00K derived: sum of 2 quarters · filed 2025-03-27 | $174.00K 10-K · filed 2025-03-27 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $64.00K 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $64.00K 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $179.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $179.00K derived: sum of 2 quarters · filed 2024-03-28 | $484.00K 10-K · filed 2024-03-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $305.00K 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $305.00K 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $0.00 derived: sum of 2 quarters · filed 2023-03-28 | $0.00 10-K · filed 2023-03-28 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |